These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2881443)

  • 1. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
    Jenner P; Rose S; Nomoto M; Marsden CD
    Adv Neurol; 1987; 45():183-6. PubMed ID: 2881443
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathology of MPTP in the marmoset.
    Gibb WR; Lees AJ; Wells FR; Barnard RO; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():187-90. PubMed ID: 3103386
    [No Abstract]   [Full Text] [Related]  

  • 3. Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
    Hassan MN; Thakar JH; Grimes JD
    Adv Neurol; 1990; 53():219-23. PubMed ID: 2239461
    [No Abstract]   [Full Text] [Related]  

  • 4. Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
    Da Prada M; Kettler R; Keller HH; Bonetti EP; Imhof R
    Adv Neurol; 1987; 45():175-8. PubMed ID: 2881442
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey.
    Chiueh CC; Markey SP; Burns RS; Johannessen JN; Jacobowitz DM; Kopin IJ
    Psychopharmacol Bull; 1984; 20(3):548-53. PubMed ID: 6332333
    [No Abstract]   [Full Text] [Related]  

  • 6. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
    Garvey J; Petersen M; Waters CM; Rose SP; Hunt S; Briggs R; Jenner P; Marsden CD
    Mov Disord; 1986; 1(2):129-34. PubMed ID: 3143064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
    Kito S; Miyoshi R; Mizuno K; Nitta K; Matsubayashi H; Yamamura Y; Tahara E
    Adv Neurol; 1987; 45():159-65. PubMed ID: 2881441
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
    Doudet D; Gross C; Lebrun-Grandie P; Bioulac B
    Electromyogr Clin Neurophysiol; 1986 Dec; 26(8):711-27. PubMed ID: 3493894
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys.
    Kuno S; Mizuta E; Sakamoto H; Ichihara K; Nagasaka M
    Clin Neuropharmacol; 1998; 21(1):35-40. PubMed ID: 9579283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
    Nomoto M; Jenner P; Marsden CD
    Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of new pharmacological approaches in Parkinson's disease.
    Carlsson A
    Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
    Gomez-Mancilla B; Boucher R; Bédard PJ
    Mov Disord; 1992; 7(1):43-7. PubMed ID: 1348351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M; Fukuda T
    Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
    [No Abstract]   [Full Text] [Related]  

  • 19. [L-threo-DOPS therapy and parkinsonism].
    Narabayashi H
    No To Shinkei; 1986 Jan; 38(1):60-2. PubMed ID: 3083844
    [No Abstract]   [Full Text] [Related]  

  • 20. [The effect of amiridin on the MPTP-induced Parkinson-like syndrome in monkeys].
    Burov IuV; Metkalova SE; Kustov AE; Petrov GV; Shul'govskiĭ VV
    Biull Eksp Biol Med; 1992 Nov; 114(11):495-7, 494. PubMed ID: 1290822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.